CSH RNA Interference Reduces Global Nutrient Uptake and Umbilical Blood Flow Resulting in Intrauterine Growth

Amelia R Tanner1, Cameron S Lynch1, Victoria C Kennedy1

  • 1College of Veterinary Medicine, Colorado State University, Fort Collins, CO 80523, USA.

Insights

Reduced chorionic somatomammotropin (CSH) impairs fetal growth, leading to intrauterine growth restriction (IUGR). CSH deficiency decreases blood flow and nutrient uptake, essential for supporting fetal and uterine development.

Area of Science:

  • Reproductive biology
  • Maternal-fetal medicine
  • Endocrinology

Background:

  • Placental hormone chorionic somatomammotropin (CSH) is crucial for fetal development.
  • CSH deficiency is linked to intrauterine growth restriction (IUGR).

Purpose of the Study:

  • To investigate the physiological effects of CSH deficiency using RNA interference (RNAi) in a sheep model.
  • To understand the role of CSH in regulating fetal and uterine growth and nutrient transfer.

Main Methods:

  • Lentiviral vector-mediated CSH-specific shRNA was used to silence CSH in sheep blastocysts.
  • Doppler ultrasonography assessed umbilical hemodynamics and fetal measurements.
  • Metabolic studies using 3H2O diffusion determined nutrient uptake rates and uteroplacental glucose utilization.

Main Results:

  • CSH RNAi significantly reduced fetal and uterine weights and umbilical blood flow.
  • Umbilical IGF1 concentrations and nutrient uptakes were decreased in CSH RNAi pregnancies.
  • Uterine nutrient uptakes and uteroplacental glucose utilization were also reduced.

Conclusions:

  • CSH is essential for maintaining adequate uteroplacental blood flow.
  • Adequate blood flow facilitated by CSH is critical for the uptake of oxygen, substrates, and hormones necessary for fetal and uterine growth.
  • CSH plays a vital role in preventing IUGR by supporting nutrient and oxygen supply to the fetus.

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.6K
RNA Editing02:23

RNA Editing

RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.3K
Translational Regulation01:29

Translational Regulation

Translational regulation in prokaryotes ensures efficient protein synthesis by controlling ribosome access to mRNA. This regulation is mediated by secondary RNA structures, including translational riboswitches, RNA thermometers, and small RNAs (sRNAs), which respond to intracellular and environmental signals to modulate gene expression.Translational RiboswitchesRiboswitches in the leader region of mRNAs can regulate translation by altering the accessibility of the Shine-Dalgarno (SD) sequence,...
287
Stringent Response in E. coli01:23

Stringent Response in E. coli

Bacterial growth is closely tied to nutrient availability, with cells proliferating exponentially under favorable conditions and entering a stationary phase when resources become scarce. This transition is mediated by a regulatory mechanism known as the stringent response, which allows bacteria to adapt to nutrient deprivation by modulating gene expression and metabolic activity.During nutrient scarcity, intracellular amino acid levels decline. It results in the accumulation of uncharged tRNAs...
100
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.2K